Minimal residual disease and b-cell subpopulation monitoring in acute b-lymphoblastic leukaemia patients treated on rall-2016 protocol

Introduction . The Russian multicentre trial on treatment of Acute Lymphoblastic Leukaemia (ALL) in adults (RALL-2016) regulates a centralised detection minimal residual disease (MRD) days 70 (end induction II), 133 consolidation III) and 190 V). Aim — the assessment tumour cell clearance normal B-cell precursor, mature plasma dynamics. Materials methods study period December 2016 August 2019 covered 59 B-ALL patients; control cohort included four allogeneic blood stem donors. MRD was performed with bone marrow samples flow cytometry. Results patient majority have reached MRD-negativity at timepoints, 60.4, 75.6 91.2% 70, 190, respectively. No correlation observed between values immunophenotype. precursors were undetected 54.4, 38.8 59.4% patients Mature B-cells fewer compared to donors’ 190. relative count did not differ significantly over therapy Conclusion RALL-2016 protocol facilitates despite reduced cytostatic intensity.